---
title: "300204.SZ (300204.SZ) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300204.SZ/news.md"
symbol: "300204.SZ"
name: "300204.SZ"
parent: "https://longbridge.com/en/quote/300204.SZ.md"
datetime: "2026-05-20T07:23:00.408Z"
locales:
  - [en](https://longbridge.com/en/quote/300204.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300204.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300204.SZ/news.md)
---

# 300204.SZ (300204.SZ) — Related News

### [Staidson BioPharm: Received approval from the CSRC for the registration of stock issuance to specific targets](https://longbridge.com/en/news/286737260.md)
*2026-05-18T08:18:15.000Z*
> On May 18th, Staidson BioPharm announced that the company received approval from the China Securities Regulatory Commiss

### ["The laxative does not laxate" has further developments, pharmaceutical companies prove their innocence by disclosing specific drug costs](https://longbridge.com/en/news/286410541.md)
*2026-05-14T11:38:29.000Z*
> On May 12th, the Shanghai Sunshine Pharmaceutical Procurement Network announced the cost information of Compound Polyeth

### [Staidson BioPharm reports six consecutive quarters of net losses due to poor sales of flagship products and costly innovation drug development](https://longbridge.com/en/news/284389854.md)
*2026-04-28T12:45:09.000Z*
> Staidson BioPharm (300204) reported losses for six consecutive years in 2025 and the first quarter of 2026, with net pro

### [Staidson BioPharm released its 2025 annual performance, with a net loss attributable to the parent company of 77.633 million yuan, narrowing by 46.31%](https://longbridge.com/en/news/284201502.md)
*2026-04-27T11:04:32.000Z*
> Staidson BioPharm released its 2025 annual report, with operating revenue of 220 million yuan, a year-on-year decrease o

### [Staidson BioPharm released its first-quarter performance, with a net loss attributable to the parent company of 8.4318 million yuan, an increase of 261.10%](https://longbridge.com/en/news/284198595.md)
*2026-04-27T10:46:10.000Z*
> Staidson BioPharm released its Q1 2026 performance, with operating revenue of 46.8977 million yuan, a year-on-year decre

### [Innovative drug concept stocks have pulled back, with Salubris and other stocks falling over 6%](https://longbridge.com/en/news/282921654.md)
*2026-04-16T01:51:44.000Z*
> Innovative drug concept stocks have pulled back, with Salubris and Cosunter down over 6%, and Staidson BioPharm and Suns

### [The innovative drug and chemical pharmaceutical sectors continued to strengthen in the afternoon, with stocks like PKU HEALTHCARE hitting the daily limit](https://longbridge.com/en/news/282787254.md)
*2026-04-15T05:24:59.000Z*
> The innovative drug and chemical pharmaceutical sectors continued to strengthen in the afternoon, with PKU HEALTHCARE, S

### [Staidson BioPharm: The progress of innovative biopharmaceutical clinical trials may be below expectations](https://longbridge.com/en/news/281178086.md)
*2026-03-31T11:22:17.000Z*
> Staidson BioPharm stock trading abnormal fluctuation announcement, the company has multiple research projects that belon